慢性心不全 (SHIFT) のリスク因子としての心拍数: ランダム化プラセボ対照試験における心拍数と結果の関連性
Michael Böhm1, Karl Swedberg, Michel Komajda
1Universitätsklinikum des Saarlandes, Klinik für Innere Medizin III, Homburg/Saar, Germany. boehm@uks.eu
Lancet (London, England)
|August 31, 2010
まとめ
高い心拍数は,心不全患者の心血管疾患のリスクを高めます. イバブラジンによる選択的な心拍数低下は,治療結果を改善し,心拍数を重要な治療目標にしています.
科学分野:
- 心臓病学 心臓病学
- クリニック・トライアル 臨床試験
- 薬理学 薬理学とは
背景:
- 休息時の心拍数上昇は,心血管疾患のリスクマーカーとして知られています.
- SHIFT試験では,慢性心不全患者の心拍数低下剤であるイバブラジンについて調査した.
- この研究は,心不全における心血管疾患の危険因子としての心拍数を確認することを目的とした.
研究 の 目的:
- 慢性心不全患者の心拍数と心血管疾患との関連を調査する.
- イバブラジンによる選択的な心拍数低下が心血管疾患のアウトカムを改善するかどうかを判断する.
- 心不全管理における治療目標として心拍数を確立する.
主な方法:
- SHIFTランダム化試験 (プラセボとイバブラジングループ) の心血管疾患のアウトカムの分析.
- 患者は,プラセボ群のベースライン心拍数クインティルによって層格化されました.
- 結果は,イバブラジン群で28日後に達成された心拍数に基づいて分析され,心拍数変化の調整を行った.
主要な成果:
- プラセボ群では,最も高い心拍数 (>87bpm) は,最も低い心拍数 (<72bpm) と比較して,プライマリ複合エンドポイントの2倍以上のリスクを示しました.
- ベースラインの心拍数における1分あたりの鼓動ごとに3%のリスク増加が観察されました.
- イバブラジン群では,低心拍数 (28日後,時速60拍以下) は事件の減少と関連しており,治療効果は心拍数の減少によって説明されました.
結論:
- 高い心拍数は,心不全の重要な危険因子として確認されています.
- イバブラジンによる選択的な心拍数低下は,心血管疾患のアウトカムを効果的に改善します.
- 心拍数は,心不全の治療において,決定的で変更可能な標的を代表しています.
関連する概念動画
01:17Pathophysiology of Heart Failure
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
01:30Factors Influencing Heart Rate
The heart rate, or pulse rate, is a vital indicator of cardiovascular health. It reflects the number of times the heart beats per minute. Various physiological and environmental factors influence heart rate, increasing or decreasing cardiac output. Understanding these factors is crucial for assessing heart function and identifying potential health issues.
Let us explore the significant factors affecting heart rate, including age, body temperature, posture, acute pain, chemical influences,...
Let us explore the significant factors affecting heart rate, including age, body temperature, posture, acute pain, chemical influences,...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...